Riley Hospital at IU Health used cryopreserved marrow from a deceased donor in a world‑first pediatric transplant, putting a 14‑year‑old with leukemia into remission.

A Baylor‑led consortium's AllFaith Benchmark finds major language models often omit religious perspectives in ethics answers and show conversion biases. The work is open‑sourced for developers and scholars.

A 12‑year‑old Center Grove student is the first in Indiana to receive an FDA‑approved gene therapy at Riley, a treatment that could end her monthly transfusions.

Eli Lilly says its experimental drug retatrutide produced near‑surgical levels of weight loss in late‑stage trials, but analysts note higher side effects and access questions.

A new Crossroads Academic Medical Institute launched in Indianapolis to coordinate clinical training across the state and widen access to care. Universities and hospital systems will share sites and curricula.

Sam Schmidt converted the old Five Seasons club into a 114,000‑sq‑ft DRIVEN Neuro Recovery Center in Carmel, pairing deep‑water therapy, robotic gait trainers and nonprofit care. The campus aims to offer long‑term rehab beyond typical insurance limits.

Mounjaro's Q1 sales topped Keytruda, lifting Lilly's revenue and reshaping the blockbuster drug ranking.

Gov. Mike Braun and business leaders launched IN AI, a statewide hub and roadshows to help Hoosier employers use human-centered AI to increase productivity and wages.

Eli Lilly agreed to buy Ajax Therapeutics for up to $2.3 billion, taking on a Cambridge biotech's experimental Type II JAK2 drug for myelofibrosis with data due in 2026.

Carmel will pilot Qwake’s C‑THRU AR helmets this summer — 16 helmets and four command tablets in a three‑year, $375K program funded with help from the Heroes Club.

Eli Lilly is reportedly in advanced talks to buy Boston‑based Kelonia Therapeutics for more than $2 billion, folding a promising in‑vivo CAR‑T program into Lilly’s pipeline.

Franciscan Alliance is moving to build an osteopathic medical school in Crown Point, with leadership roles posted and campus work already under way.

A federal appeals court revived Teva’s patent fight with Eli Lilly and sent the case back to Massachusetts, reopening a dispute that once produced a $176.5M jury award.